RÉSUMÉ
BACKGROUND: Biologic therapies inhibiting the IL-4 or IL-5 pathways are very effective in the treatment of asthma and other related conditions. However, the cytokines IL-4 and IL-5 also play a role in the generation of adaptive immune responses. Although these biologics do not cause overt immunosuppression, their effect in primary severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunization has not been studied completely. OBJECTIVE: Our aim was to evaluate the antibody and cellular immunity after SARS-CoV-2 mRNA vaccination in patients on biologics (PoBs). METHODS: Patients with severe asthma or atopic dermatitis who were taking benralizumab, dupilumab, or mepolizumab and had received the initial dose of the 2-dose adult SARS-CoV-2 mRNA vaccine were enrolled in a prospective, observational study. As our control group, we used a cohort of immunologically healthy subjects (with no significant immunosuppression) who were not taking biologics (NBs). We used a multiplexed immunoassay to measure antibody levels, neutralization assays to assess antibody function, and flow cytometry to quantitate Spike-specific lymphocytes. RESULTS: We analyzed blood from 57 patients in the PoB group and 46 control subjects from the NB group. The patients in the PoB group had lower levels of SARS-CoV-2 antibodies, pseudovirus neutralization, live virus neutralization, and frequencies of Spike-specific B and CD8 T cells at 6 months after vaccination. In subgroup analyses, patients with asthma who were taking biologics had significantly lower pseudovirus neutralization than did subjects with asthma who were not taking biologics. CONCLUSION: The patients in the PoB group had reduced SARS-CoV-2-specific antibody titers, neutralizing activity, and virus-specific B- and CD8 T-cell counts. These results have implications when considering development of a more individualized immunization strategy in patients who receive biologic medications blocking IL-4 or IL-5 pathways.
Sujet(s)
Anticorps monoclonaux humanisés , Asthme , Vaccins contre la COVID-19 , COVID-19 , SARS-CoV-2 , Humains , Anticorps monoclonaux humanisés/usage thérapeutique , Anticorps monoclonaux humanisés/administration et posologie , Mâle , Femelle , SARS-CoV-2/immunologie , Adulte d'âge moyen , Adulte , COVID-19/immunologie , COVID-19/prévention et contrôle , Asthme/traitement médicamenteux , Asthme/immunologie , Vaccins contre la COVID-19/immunologie , Vaccins contre la COVID-19/administration et posologie , Anticorps antiviraux/sang , Anticorps antiviraux/immunologie , Eczéma atopique/traitement médicamenteux , Eczéma atopique/immunologie , Études prospectives , Sujet âgé , Vaccination , Interleukine-5/antagonistes et inhibiteurs , Interleukine-5/immunologieRÉSUMÉ
Wheezing is a critical indicator of various respiratory conditions, including asthma and chronic obstructive pulmonary disease (COPD). Current diagnosis relies on subjective lung auscultation by physicians. Enabling this capability via a low-profile, objective wearable device for remote patient monitoring (RPM) could offer pre-emptive, accurate respiratory data to patients. With this goal as our aim, we used a low-profile accelerometer-based wearable system that utilizes deep learning to objectively detect wheezing along with respiration rate using a single sensor. The miniature patch consists of a sensitive wideband MEMS accelerometer and low-noise CMOS interface electronics on a small board, which was then placed on nine conventional lung auscultation sites on the patient's chest walls to capture the pulmonary-induced vibrations (PIVs). A deep learning model was developed and compared with a deterministic time-frequency method to objectively detect wheezing in the PIV signals using data captured from 52 diverse patients with respiratory diseases. The wearable accelerometer patch, paired with the deep learning model, demonstrated high fidelity in capturing and detecting respiratory wheezes and patterns across diverse and pertinent settings. It achieved accuracy, sensitivity, and specificity of 95%, 96%, and 93%, respectively, with an AUC of 0.99 on the test set-outperforming the deterministic time-frequency approach. Furthermore, the accelerometer patch outperforms the digital stethoscopes in sound analysis while offering immunity to ambient sounds, which not only enhances data quality and performance for computational wheeze detection by a significant margin but also provides a robust sensor solution that can quantify respiration patterns simultaneously.
Sujet(s)
Apprentissage profond , Dispositifs électroniques portables , Humains , Fréquence respiratoire , Bruits respiratoires/diagnostic , AccélérométrieRÉSUMÉ
BACKGROUND: Alcohol exposure induces TGFß1 and renders the lung susceptible to injury and disrepair. We determined that TGFß1 regulates myofibroblast differentiation through the loss of Thy-1 expression and consequent induction of α-SMA. TGFß1 is important for T helper 17 (Th17) differentiation and IL-17 secretion, which in turn participates in tissue repair. We hypothesized that alcohol induces Th17 differentiation via TGFß1 and that IL-17 produced by these cells contributes to the development of profibrotic lung myofibroblasts. METHODS: Primary lung fibroblasts (PLFs) were treated with alcohol, TGFß1, and IL-17 and then analyzed for Thy-1 expression and cell morphology. Naïve and Th17-polarized CD4+ T cells were exposed to alcohol and assessed for IL-17 expression. CD4+ T cells from alcohol-fed mice were analyzed for Th17 and IL-17 expression. Lungs of control-fed, bleomycin-treated and alcohol-fed, bleomycin-treated mice were analyzed for IL-17 protein expression. RESULTS: Alcohol-treated PLFs expressed lower levels of Thy-1 than untreated cells. TGFß1 or IL-17 exposure suppressed PLF Thy-1 expression. When administered together, TGFß1 and IL-17 additively down-regulated Thy-1 expression. Exposure of naïve and Th17-polarized CD4+ T cells to alcohol induced the Th17 phenotype and augmented their production of IL-17. CD4+ Th17+ levels are elevated in the peripheral compartment but not in the lungs of alcohol-fed animals. Treatment of the PLFs with IL-17 and alcohol induced α-SMA expression. Induction of α-SMA and myofibroblast morphology by IL-17 occurred selectively in a Thy-1- fibroblast subpopulation. Chronic alcohol ingestion augmented lung-specific IL-17 expression following bleomycin-induced lung injury. CONCLUSIONS: Alcohol exposure skews T cells toward a Th17 immune response that in turn primes the lung for fibroproliferative disrepair through loss of Thy-1 expression and induction of myofibroblast differentiation. These effects suggest that IL-17 and TGFß1 contribute to fibroproliferative disrepair in the lung and targeting these proteins could limit morbidity and mortality following lung injury in alcoholic individuals.
Sujet(s)
Différenciation cellulaire/effets des médicaments et des substances chimiques , Dépresseurs du système nerveux central/pharmacologie , Éthanol/pharmacologie , Fibroblastes/effets des médicaments et des substances chimiques , Interleukine-17/biosynthèse , Poumon/anatomopathologie , Myofibroblastes/effets des médicaments et des substances chimiques , Antigènes Thy-1/biosynthèse , Antigènes Thy-1/génétique , Actines/biosynthèse , Actines/génétique , Animaux , Numération des lymphocytes CD4 , Transdifférenciation cellulaire/effets des médicaments et des substances chimiques , Régulation négative/effets des médicaments et des substances chimiques , Poumon/effets des médicaments et des substances chimiques , Lymphotoxine alpha/biosynthèse , Souris , Souris de lignée C57BL , Lymphocytes T/effets des médicaments et des substances chimiquesRÉSUMÉ
Respiratory complications occur frequently in individuals living with human immunodeficiency-1 virus (HIV) infection, and there is evidence that HIV-related oxidative stress impairs alveolar macrophage immune function. We hypothesized that nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a master transcription factor that activates the antioxidant response element (ARE) and regulates antioxidant defenses, has an important role in alveolar macrophage (AMs) immune dysfunction in individuals with HIV infections. To test that hypothesis, we analyzed human monocyte-derived macrophages (MDMs) that were either infected with HIV-1 or were exposed to the HIV-related proteins gp120 and Tat ex vivo and determined that either stress affected the expression of Nrf2 and the Nrf2-ARE-dependent genes for NAD(P)H dehydrogenase, quinone 1 (NQO1) and glutamate-cysteine ligase, catalytic subunit (GCLC). We then determined that the expression of Nrf2, NQO1, and GCLC was significantly decreased in primary AMs isolated from HIV-1 transgenic rats. In parallel, treating a rat macrophage cell line (NR8383 cells) with the HIV-related proteins gp120 or Tat similarly decreased the gene and protein expression of Nrf2, NQO1, and GCLC. Further, phagocytic function was decreased in both human MDMs infected with HIV-1 and primary AMs from HIV-1 transgenic rats. Importantly, treating HIV-1-infected human MDMs or AMs from HIV-1 transgenic rats with sulforaphane (SFN, an Nrf2 activator) significantly improved their phagocytic function. The salutary effects of SFN were abrogated by silencing RNA to Nrf2 in wild-type rat macrophages. Our findings demonstrate that HIV-1 infection and exposure to HIV-1-related proteins inhibit Nrf2-ARE activity in the AMs and impair their phagocytic function. Treatments targeted at increasing Nrf2-ARE activity could, therefore, enhance lung innate immunity in people living with HIV-1.
Sujet(s)
Éléments de réponse aux anti-oxydants/immunologie , Régulation de l'expression des gènes/immunologie , Infections à VIH/immunologie , Macrophages alvéolaires/immunologie , Facteur-2 apparenté à NF-E2/immunologie , Animaux , Technique de Western , VIH-1 (Virus de l'Immunodéficience Humaine de type 1)/immunologie , Humains , Macrophages alvéolaires/virologie , Facteur-2 apparenté à NF-E2/métabolisme , Phagocytose/immunologie , Rats , Rats de lignée F344 , Rats transgéniques , Réaction de polymérisation en chaine en temps réelRÉSUMÉ
Idiopathic pulmonary fibrosis is a progressive lung disease that increases in incidence with age. We identified a profibrotic lung phenotype in aging mice characterized by an increase in the number of fibroblasts lacking the expression of thymocyte differentiation antigen 1 (Thy-1) and an increase in transforming growth factor (TGF)-ß1 expression. It has been shown that Thy-1 expression can be epigenetically modified. Lung fibroblasts (PLFs) were treated with TGF-ß1 ± DNA methyltransferase (DNMT) inhibitor 5-aza-2'-deoxycytidine (5-AZA) and analyzed for Thy-1 gene and protein expression, DNMT protein expression, and activity. α-Smooth muscle actin (α-SMA) and collagen type 1 (Col1A1) gene and protein expression was assessed. PLFs were transfected with DNMT1 silencing RNA ± TGF-ß1. TGF-ß1 inhibited Thy-1 gene and protein expression in PLFs, and cotreatment with 5-AZA ameliorated this effect and appeared to inhibit DNMT1 activation. TGF-ß1 induced Thy-1 promoter methylation as assessed by quantitative methyl PCR. Treatment with 5-AZA attenuated TGF-ß1-induced Col1A1 gene and protein expression and α-SMA gene expression (but not α-SMA protein expression). Inhibiting DNMT1 with silencing RNA attenuated TGF-ß1-induced DNMT activity and its downstream suppression of Thy-1 mRNA and protein expression as well as inhibited α-SMA mRNA and Col1A1 mRNA and protein expression, and showed a decreased trend in Thy-1 promoter methylation. Immunofluorescence for α-SMA suggested that 5-AZA inhibited stress fiber formation. These findings suggest that TGF-ß1 epigenetically regulates lung fibroblast phenotype through methylation of the Thy-1 promoter. Targeted inhibition of DNMT in the right clinical context might prevent fibroblast to myofibroblast transdifferentiation and collagen deposition, which in turn could prevent fibrogenesis in the lung and other organs.
Sujet(s)
Méthylation de l'ADN/effets des médicaments et des substances chimiques , Épigenèse génétique/effets des médicaments et des substances chimiques , Fibroblastes/effets des médicaments et des substances chimiques , Fibrose pulmonaire idiopathique/génétique , Poumon/effets des médicaments et des substances chimiques , Antigènes Thy-1/génétique , Facteur de croissance transformant bêta-1/pharmacologie , Actines/génétique , Actines/métabolisme , Animaux , Séquence nucléotidique , Transdifférenciation cellulaire , Cellules cultivées , Collagène de type I/génétique , Collagène de type I/métabolisme , Chaine alpha-1 du collagène de type I , DNA (Cytosine-5-)-methyltransferase 1 , DNA (cytosine-5-)-methyltransferase/antagonistes et inhibiteurs , DNA (cytosine-5-)-methyltransferase/génétique , DNA (cytosine-5-)-methyltransferase/métabolisme , Antienzymes/pharmacologie , Fibroblastes/métabolisme , Fibroblastes/anatomopathologie , Fibrose pulmonaire idiopathique/métabolisme , Fibrose pulmonaire idiopathique/anatomopathologie , Poumon/métabolisme , Poumon/anatomopathologie , Souris de lignée C57BL , Données de séquences moléculaires , Phénotype , Régions promotrices (génétique) , Interférence par ARN , Antigènes Thy-1/métabolisme , TransfectionRÉSUMÉ
Alveolar macrophage (AM) immune function depends on the activation of the transcription factor PU.1 by granulocyte macrophage colony-stimulating factor. We have determined that chronic alcohol ingestion dampens PU.1 signaling via an unknown zinc-dependent mechanism; specifically, although PU.1 is not known to be a zinc-dependent transcription factor, zinc treatment reversed alcohol-mediated dampening of PU.1 signaling. Nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a zinc-dependent basic leucine zipper protein essential for antioxidant defenses, is also impaired by chronic alcohol ingestion and enhanced by zinc treatment. We hypothesized that the response of PU.1 to zinc treatment may result from the action of Nrf2 on PU.1. We first performed Nrf2/PU.1 protein coimmunoprecipitation on a rat AM cell line (NR8383) and found no evidence of protein-protein interactions. We then found evidence of increased Nrf2 binding to the PU.1 promoter region by chromatin immunoprecipitation. We next activated Nrf2 using either sulforaphane or an overexpression vector and inhibited Nrf2 with silencing RNA to determine whether Nrf2 could actively regulate PU.1. Nrf2 activation increased protein expression of both factors as well as gene expression of their respective downstream effectors, NAD(P)H dehydrogenase[quinone] 1 (NQO1) and cluster of differentiation antigen-14 (CD14). In contrast, Nrf2 silencing decreased the expression of both proteins, as well as gene expression of their effectors. Activating and inhibiting Nrf2 in primary rat AMs resulted in similar effects. Taken together, these findings suggest that Nrf2 regulates the expression and activity of PU.1 and that antioxidant response and immune activation are coordinately regulated within the AM.
Sujet(s)
Régulation de l'expression des gènes , Macrophages alvéolaires/métabolisme , Facteur-2 apparenté à NF-E2/métabolisme , Protéines proto-oncogènes/biosynthèse , Éléments de réponse , Transactivateurs/biosynthèse , Animaux , Lignée cellulaire , Antigènes CD14/génétique , Antigènes CD14/métabolisme , Macrophages alvéolaires/cytologie , NADPH dehydrogenase (quinone)/génétique , NADPH dehydrogenase (quinone)/métabolisme , Facteur-2 apparenté à NF-E2/génétique , Protéines proto-oncogènes/génétique , Rats , Rats de lignée F344 , Transactivateurs/génétique , Zinc/pharmacologieRÉSUMÉ
Macrophage phenotype and function is dependent on the underlying microenvironment. Many diseases are accompanied by abnormal shifts in macrophage polarization state that limit the ability of the cells to become innate immune effectors. Previous work in the field suggests that chronic alcohol ingestion, which is associated with a shift away from innate immune effector macrophages, is also associated with a deficient response to oxidative stress. We therefore hypothesized that the optimal response to oxidative stress was dependent on the ability of the macrophage to become an innate immune effector cell. To investigate this hypothesis, we first confirmed that we could reproducibly polarize NR8383 cells (a rat alveolar macrophage cell line) into the prototypical M1 and M2 states (using IFN-γ and IL-4, respectively). We then tested the polarized cells for their ability to scavenge reactive oxygen species generated by glucose oxidase (GOX) using the Amplex red assay and found that IFN-γ-polarized cells had greater scavenging capacity. To elucidate the mechanism of the enhanced response to oxidative stress, we then assessed key components of the anti-oxidant response; specifically, nuclear factor (erythroid-derived 2)-like 2 (Nrf2), the master transcription factor responsible for the cellular response to oxidative stress, and one of its downstream effectors, glutamate-cysteine ligase catalytic subunit (GCLC). We found that both proteins were significantly upregulated in the IFN-γ-polarized cells. To confirm that Nrf2 is an integral component of this improved anti-oxidant response, we transfected IFN-γ-polarized cells with either silencing RNA to Nrf2 or control silencing RNA and found that hydrogen peroxide scavenging was significantly impaired in the si-Nrf2-treated cells. Further, transfecting untreated cells with si-Nrf2 polarized them toward the M2 phenotype in the absence of IL-4, suggesting a mechanistic role for Nrf2 in macrophage polarization. We then confirmed several of our key experiments in primary rat alveolar macrophages cells. Taken together, these findings suggest that the M1 polarization state is necessary for the optimal response to oxidative stress in the macrophage, and that this response is mediated through Nrf2 and its downstream effectors.
RÉSUMÉ
Fibrotic lung diseases increase with age. Previously we determined that senescence increases tissue expression of fibronectin EDA (Fn-EDA) and decreases fibroblast expression of Thy-1, and that fibrocytes contribute to fibrosis following bleomycin-induced lung injury in mice. In this study we hypothesized that fibroblasts lacking Thy-1 expression produce an extracellular matrix that promotes fibrocyte retention and myofibroblast transdifferentiation, thereby promoting fibrogenesis. Young and old mice were treated with bleomycin intratracheally; fibrocytes in the bone marrow, blood, and lungs were quantified, and lung fibroblast Thy-1 expression assessed. Bone marrow-derived fibrocytes were cultured on matrices derived from Thy-1(+) or Thy-1(-) fibroblasts ± the pro-fibrotic cytokine TGFß1. Older mice had more fibrocytes in their bone marrows at baseline and more fibrocytes in their lungs following bleomycin treatment. In parallel, lung fibroblasts in older mice had lower expression of Thy-1 at baseline that increased transiently 7 days after bleomycin treatment but then rapidly waned such that 14 days after bleomycin treatment Thy-1 expression was again markedly lower. Fibrocytes cultured on matrices derived from Thy-1(-) fibroblasts + TGFß1 had increased gene expression for collagen type 1, fibronectin, Fn-EDA, and α-smooth muscle actin. In parallel, whereas the matrices derived from Thy-1(-) fibroblasts stimulated phosphorylation of Akt in cultured fibrocytes, the matrices derived from Thy-1(+) fibroblasts induced apoptosis. These findings suggest that senescence increases fibrocyte recruitment to the lung following injury and that loss of Thy-1 expression by lung fibroblasts promotes fibrocyte retention and myofibroblast trans-differentiation that renders the "aging lung" susceptible to fibrosis.
RÉSUMÉ
In addition to immune cells, airway epithelial cells can contribute to and shape the immune response in the lung by secreting specific cytokines. IL-6 is a key factor in determining the effector fate of CD4(+) T cells. Here we show that under basal conditions, the IL-6 gene is already highly expressed in lung epithelial cells, but not in immune cells resident in the lung. However, upon exposure of the lungs to fungal allergens, the direct contact of ß-glucans present in the fungus cell wall with lung epithelial cells is sufficient to trigger the rapid synthesis and secretion of IL-6 protein. This posttranscriptional regulation of IL-6 in response to fungal extracts is mediated by the p38 mitogen-activated protein kinase pathway. The inhalation of ß-glucans with a nonallergenic antigen is sufficient to provide an adjuvant effect that leads to mucous hyperplasia in the airways. Thus, ß-glucans may constitute a common determinant of the fungal and plant-derived allergens responsible for some of the pathological features in allergic asthma.
Sujet(s)
Allergènes/immunologie , Aspergillus fumigatus/immunologie , Asthme/immunologie , Lymphocytes T CD4+/immunologie , Cellules épithéliales/immunologie , Régulation de l'expression des gènes/immunologie , Interleukine-6/immunologie , Muqueuse respiratoire/immunologie , bêta-Glucanes/immunologie , p38 Mitogen-Activated Protein Kinases/immunologie , Allergènes/composition chimique , Allergènes/pharmacologie , Animaux , Aspergillus fumigatus/composition chimique , Asthme/métabolisme , Asthme/anatomopathologie , Lymphocytes T CD4+/métabolisme , Lymphocytes T CD4+/anatomopathologie , Cellules cultivées , Cellules épithéliales/métabolisme , Cellules épithéliales/anatomopathologie , Régulation de l'expression des gènes/effets des médicaments et des substances chimiques , Interleukine-6/métabolisme , Poumon/immunologie , Poumon/métabolisme , Poumon/anatomopathologie , Système de signalisation des MAP kinases/effets des médicaments et des substances chimiques , Système de signalisation des MAP kinases/immunologie , Souris , Souris knockout , Muqueuse respiratoire/métabolisme , Muqueuse respiratoire/anatomopathologie , bêta-Glucanes/composition chimique , bêta-Glucanes/pharmacologie , p38 Mitogen-Activated Protein Kinases/métabolismeRÉSUMÉ
BACKGROUND: Asthma is a chronic inflammatory disease of the airway that is characterized by a Th2-type of immune response with increasing evidence for involvement of Th17 cells. The role of IL-6 in promoting effector T cell subsets suggest that IL-6 may play a functional role in asthma. Classically IL-6 has been viewed as an inflammatory marker, along with TNFalpha and IL-1beta, rather than as regulatory cytokine. OBJECTIVE: To investigate the potential relationship between IL-6 and other proinflammatory cytokines, Th2/Th17 cytokines and lung function in allergic asthma, and thus evaluate the potential role of IL-6 in this disease. METHODS: Cytokine levels in induced sputum and lung function were measured in 16 healthy control and 18 mild-moderate allergic asthmatic subjects. RESULTS: The levels of the proinflammatory biomarkers TNFalpha and IL-1beta were not different between the control and asthmatic group. In contrast, IL-6 levels were specifically elevated in asthmatic subjects compared with healthy controls (p < 0.01). Hierarchical regression analysis in the total study cohort indicates that the relationship between asthma and lung function could be mediated by IL-6. Among Th2 cytokines only IL-13 (p < 0.05) was also elevated in the asthmatic group, and positively correlated with IL-6 levels (rS = 0.53, p < 0.05). CONCLUSIONS: In mild-moderate asthma, IL-6 dissociates from other proinflammatory biomarkers, but correlates with IL-13 levels. Furthermore, IL-6 may contribute to impaired lung function in allergic asthma.
Sujet(s)
Asthme/immunologie , Cytokines/immunologie , Interleukine-6/immunologie , Poumon/immunologie , Pneumopathie infectieuse/immunologie , Hypersensibilité respiratoire/immunologie , Adulte , Femelle , Humains , Mâle , Pneumopathie infectieuse/complicationsRÉSUMÉ
Allergic asthma is caused by inhaled allergens and is characterized by airway eosinophilia, as well as mucus hypersecretion, which can lead to airflow obstruction. Despite the association of increased IL-6 levels with human atopic asthma, the contribution of IL-6 to the development of allergic airway inflammation triggered by inhaled allergens remains unclear. In this study, we examined the role of IL-6 in a mouse model of allergic airway inflammation induced by direct airway exposure to extracts of Aspergillus fumigatus, a common allergen in humans. We show that inhaled A. fumigatus extracts rapidly trigger the production of IL-6 in the airways. IL-6 appears to be dispensable for the recruitment of eosinophils to the lung during the development of allergic airway inflammation. However, IL-6 is essential for mucus hypersecretion by airway epithelial cells triggered in response to inhaled A. fumigatus Ags. Impaired mucus production caused by IL-6 deficiency correlates with a severe reduction in the levels of IL-13, a major inducer of mucin glycoproteins. Thus, IL-6 is a key regulator of specific hallmark features of allergic airway inflammation and it could be a potential target for pulmonary diseases that are associated with goblet cell metaplasia and mucus hypersecretion.
Sujet(s)
Allergènes/immunologie , Antigènes fongiques/immunologie , Interleukine-6/immunologie , Mucines/biosynthèse , Appareil respiratoire/immunologie , Animaux , Aspergillus fumigatus/immunologie , Cellules épithéliales/métabolisme , Cellules épithéliales/anatomopathologie , Hypersensibilité , Inflammation , Interleukine-6/biosynthèse , Souris , Mucus/métabolismeRÉSUMÉ
Interleukin (IL) 6 is a proinflammtory cytokine produced by antigen-presenting cells and nonhematopoietic cells in response to external stimuli. It was initially identified as a B cell growth factor and inducer of plasma cell differentiation in vitro and plays an important role in antibody production and class switching in vivo. However, it is not clear whether IL-6 directly affects B cells or acts through other mechanisms. We show that IL-6 is sufficient and necessary to induce IL-21 production by naive and memory CD4(+) T cells upon T cell receptor stimulation. IL-21 production by CD4(+) T cells is required for IL-6 to promote B cell antibody production in vitro. Moreover, administration of IL-6 with inactive influenza virus enhances virus-specific antibody production, and importantly, this effect is dependent on IL-21. Thus, IL-6 promotes antibody production by promoting the B cell helper capabilities of CD4(+) T cells through increased IL-21 production. IL-6 could therefore be a potential coadjuvant to enhance humoral immunity.
Sujet(s)
Production d'anticorps/physiologie , Lymphocytes T CD4+/métabolisme , Interleukine-6/physiologie , Interleukines/métabolisme , Animaux , Anticorps antiviraux/sang , Anticorps antiviraux/immunologie , Production d'anticorps/effets des médicaments et des substances chimiques , Lymphocytes B/effets des médicaments et des substances chimiques , Lymphocytes B/métabolisme , Lymphocytes T CD4+/cytologie , Lymphocytes T CD4+/effets des médicaments et des substances chimiques , Cytokines/génétique , Cytokines/métabolisme , Cytokines/pharmacologie , Test ELISA/méthodes , Expression des gènes , Immunoglobuline G/sang , Immunoglobuline G/métabolisme , Immunoglobuline M/sang , Immunoglobuline M/immunologie , Interleukine-6/génétique , Interleukine-6/pharmacologie , Sous-unité alpha du récepteur à l'interleukine-6/métabolisme , Interleukines/génétique , Interleukines/pharmacologie , Activation des lymphocytes/effets des médicaments et des substances chimiques , Souris , Souris de lignée C57BL , Lignées consanguines de souris , Souris knockout , Souris transgéniques , Orthomyxoviridae/immunologie , Récepteurs aux antigènes des cellules T/métabolisme , Récepteurs à l'interleukine-21/génétique , Récepteurs à l'interleukine-21/métabolismeRÉSUMÉ
Methylation-controlled J protein (MCJ) is a newly identified member of the DnaJ family of cochaperones. Hypermethylation-mediated transcriptional silencing of the MCJ gene has been associated with increased chemotherapeutic resistance in ovarian cancer. However, the biology and function of MCJ remain unknown. Here we show that MCJ is a type II transmembrane cochaperone localized in the Golgi network and present only in vertebrates. MCJ is expressed in drug-sensitive breast cancer cells but not in multidrug-resistant cells. The inhibition of MCJ expression increases resistance to specific drugs by inducing expression of the ABCB1 drug transporter that prevents intracellular drug accumulation. The induction of ABCB1 gene expression is mediated by increased levels of c-Jun due to an impaired degradation of this transcription factor in the absence of MCJ. Thus, MCJ is required in these cells to prevent c-Jun-mediated expression of ABCB1 and maintain drug response.
Sujet(s)
Protéines du choc thermique HSP40/métabolisme , Transporteurs d'anions organiques/génétique , Maturation post-traductionnelle des protéines , Protéines proto-oncogènes c-jun/métabolisme , Sous-famille B de transporteurs à cassette liant l'ATP , Glycoprotéine P , Séquence d'acides aminés , Animaux , Antinéoplasiques/pharmacologie , Tumeurs du sein/génétique , Tumeurs du sein/anatomopathologie , Lignée cellulaire tumorale , Séquence conservée , Régulation négative/effets des médicaments et des substances chimiques , Multirésistance aux médicaments/effets des médicaments et des substances chimiques , Résistance aux médicaments antinéoplasiques/effets des médicaments et des substances chimiques , Femelle , Régulation de l'expression des gènes tumoraux/effets des médicaments et des substances chimiques , Appareil de Golgi/effets des médicaments et des substances chimiques , Appareil de Golgi/ultrastructure , Protéines du choc thermique HSP40/composition chimique , Protéines du choc thermique HSP40/déficit , Protéines du choc thermique HSP40/génétique , Humains , Protéines membranaires/composition chimique , Protéines membranaires/déficit , Protéines membranaires/génétique , Protéines membranaires/métabolisme , Modèles biologiques , Données de séquences moléculaires , Transporteurs d'anions organiques/métabolisme , Phylogenèse , Maturation post-traductionnelle des protéines/effets des médicaments et des substances chimiques , Transport des protéines/effets des médicaments et des substances chimiques , Protéines proto-oncogènes c-jun/génétique , ARN messager/génétique , ARN messager/métabolisme , Transcription génétique/effets des médicaments et des substances chimiques , VertébrésRÉSUMÉ
Syndecan-4 is a transmembrane heparan sulfate proteoglycan that co-operates with integrins during cell-matrix interactions for the assembly of focal adhesions and actin stress fibers and in the phosphorylation of focal adhesion kinase (FAK) on Tyr397. These cellular events are regulated by the small GTPase Rho, and in the absence of syndecan-4 ligation, cellular levels of GTP-bound Rho are decreased implicating syndecan-4 in the regulation of the small GTPases. In the present study we report that, compared with wild type cells, fibronectin-adherent syndecan-4-null fibroblasts showed enhanced lamellipodia and increased Rac1 activity that could be down-regulated by re-expression of syndecan-4 in the mutant cells. Consistent with the role for Rac1 in activating p38 and JNK signaling, syndecan-4-null cells display higher levels of active p38 MAPK and JNK that were abolished by the expression of a dominant-negative RacN17 mutant. Since p38 and JNK regulate gene expression by phosphorylating and activating transcription factors, we compared both the phosphorylation state and the transcriptional activity of the ATF-2 transcription factor, as a direct p38 and JNK target in syndecan-4-null and wild type cells. In the absence of syndecan-4, both ATF-2 phosphorylation and transcriptional activity were significantly more elevated compared with wild type cells, and both activities were decreased either by the re-expression of syndecan-4 or by the expression of RacN17. Our results reveal a novel function for syndecan-4 in modulating nuclear transcriptional activity and indicate an underlying mechanism that acts at the level of Rac1-p38/JNK signaling.
Sujet(s)
Protéine de liaison à l'élément de réponse à l'AMP cyclique/métabolisme , Régulation de l'expression des gènes , Glycoprotéines membranaires/physiologie , Protéoglycanes/physiologie , Facteurs de transcription/métabolisme , Protéine G rac1/métabolisme , Facteur de transcription ATF-2 , Adenoviridae/génétique , Animaux , Noyau de la cellule/métabolisme , ADN/métabolisme , Fibroblastes/métabolisme , Fibronectines/métabolisme , Contacts focaux , Protéines à fluorescence verte/métabolisme , Humains , JNK Mitogen-Activated Protein Kinases/métabolisme , Luciferases/métabolisme , MAP Kinase Kinase 4 , Glycoprotéines membranaires/métabolisme , Souris , Mitogen-Activated Protein Kinase Kinases/métabolisme , Phosphorylation , Protéoglycanes/métabolisme , Transduction du signal , Syndécane-4 , Transcription génétique , Activation de la transcription , Tyrosine/composition chimique , p38 Mitogen-Activated Protein Kinases/métabolismeRÉSUMÉ
Syndecan-4 and integrins are the primary transmembrane receptors of focal adhesions in cells adherent to extracellular matrix molecules. Syndesmos is a cytoplasmic protein that interacts specifically with the cytoplasmic domain of syndecan-4, and it co-localizes with syndecan-4 in focal contacts. In the present study we sought possible interactors with syndesmos. We find that syndesmos interacts with the focal adhesion adaptor protein paxillin. The binding of syndesmos to paxillin is direct, and these interactions are triggered by the activation of protein kinase C. Syndesmos also binds the paxillin homolog, Hic-5. The connection of syndecan-4 with paxillin through syndesmos parallels the connection between paxillin and integrins and may thus reflect the cooperative signaling of these two receptors in the assembly of focal adhesions and actin stress fibers.